LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer

Lu,Lu; Yuan,Xueli; Zhang,Qiang; Zhang,Hong; Shen,Baozhong

doi:10.3892/mmr.2017.6262

LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer

Authors:
- Lu Lu
- Xueli Yuan
- Qiang Zhang
- Hong Zhang
- Baozhong Shen
View Affiliations

Affiliations: Department of Medical Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Center for Stem Cell and Translational Medicine, School of Life Sciences, Anhui University, Hefei, Anhui 230601, P.R. China, Molecular Imaging Center, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: February 28, 2017 https://doi.org/10.3892/mmr.2017.6262
Pages: 2015-2022
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lemur tyrosine kinase-3 (LMTK3) is a member of the serine/threonine tyrosine kinase family, which is thought to be involved in tumor progression and prognosis. The purpose of the present study was to determine the diagnostic significance and therapeutic targets in thyroid cancer. ELISA assay was used to detect the protein expression of serum LMTK3. Immunohistochemistry and reverse transcription‑quantitative polymerase chain reaction were employed to measure the expression of LMTK3. Flow cytometry was used to determine the cell cycle. Transwell assay was used to measure the invasion and migration of SW579 cells and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay to detect cell apoptosis. The LMTK3 level was positively associated with disease stage and pathological type, whereas there was no correlation between LMTK3 level and gender, age, tumor size or lymph node metastasis. The serum LMTK3 level was significantly increased in 102 thyroid carcinoma patients compared with 52 benign thyroid tumor patients and 50 healthy volunteers (P=0.001). The protein and mRNA expression of LMTK3 was markedly higher in thyroid cancer patients compared with patients with benign thyroid tumors. Notably, LMTK3 knockdown retarded proliferation, invasion and migration in SW579 cells. In addition, downregulation of LMTK3 promoted apoptosis in SW579 cells. These findings indicated that LMTK3 knockdown retards the growth of thyroid cancer cells partly through inhibiting proliferation, invasion, migration and inducing apoptosis in SW579 cells. It may serve as a useful diagnostic biomarker and a novel therapeutic target for patients with thyroid cancer.

View Figures

View References

1	Ito Y, Nikiforov YE, Schlumberger M and Vigneri R: Increasing incidence of thyroid cancer: Controversies explored. Nat Rev Endocrinol. 9:178–184. 2013. View Article : Google Scholar : PubMed/NCBI
2	Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, et al: International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control. 20:525–531. 2009. View Article : Google Scholar : PubMed/NCBI
3	Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
4	Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see commetns]. Cancer. 83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
5	Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013. View Article : Google Scholar : PubMed/NCBI
6	Omur O and Baran Y: An update on molecular biology of thyroid cancers. Crit Rev Oncol Hematol. 90:233–252. 2014. View Article : Google Scholar : PubMed/NCBI
7	Huang IC, Chou FF, Liu RT, Tung SC, Chen JF, Kuo MC, Hsieh CJ and Wang PW: Long-term outcomes of distant metastasis from differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 76:439–447. 2012. View Article : Google Scholar : PubMed/NCBI
8	Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 246:466–471. 2007. View Article : Google Scholar : PubMed/NCBI
9	Shen WT, Ogawa L, Ruan D, Suh I, Duh QY and Clark OH: Central neck lymph node dissection for papillary thyroid cancer: The reliability of surgeon judgment in predicting which patients will benefit. Surgery. 148:398–403. 2010. View Article : Google Scholar : PubMed/NCBI
10	Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH and Chung EJ: Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. 20:147–152. 2010. View Article : Google Scholar : PubMed/NCBI
11	Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG and Gulec SA: Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med. 44:451–456. 2003.PubMed/NCBI
12	Wartofsky L, Sherman SI, Gopal J, Schlumberger M and Hay ID: The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 83:4195–4203. 1998. View Article : Google Scholar : PubMed/NCBI
13	Bhaijee F and Nikiforov YE: Molecular analysis of thyroid tumors. Endocr Pathol. 22:126–133. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nikiforov YE: Molecular analysis of thyroid tumors. Mod Pathol. 24 Suppl 2:S34–S43. 2011. View Article : Google Scholar : PubMed/NCBI
15	Henderson BE and Feigelson HS: Hormonal carcinogenesis. Carcinogenesis. 21:427–433. 2000. View Article : Google Scholar : PubMed/NCBI
16	Chen GG, Vlantis AC, Zeng Q and van Hasselt CA: Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets. 8:367–377. 2008. View Article : Google Scholar : PubMed/NCBI
17	Rahbari R, Zhang L and Kebebew E: Thyroid cancer gender disparity. Future Oncol. 6:1771–1779. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kansakar E, Chang YJ, Mehrabi M and Mittal V: Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer. Am Surg. 75:785–789. 2009.PubMed/NCBI
19	Lee HR, Kim TH and Choi KC: Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse. Lab Anim Res. 28:71–76. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zeng Q, Chen GG, Vlantis AC and van Hasselt CA: Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif. 40:921–935. 2007. View Article : Google Scholar : PubMed/NCBI
21	Inoue T, Kon T, Ohkura R, Yamakawa H, Ohara O, Yokota J and Sutoh K: BREK/LMTK2 is a myosin VI-binding protein involved in endosomal membrane trafficking. Genes Cells. 13:483–495. 2008. View Article : Google Scholar : PubMed/NCBI
22	Naik S, Dothager RS, Marasa J, Lewis CL and Piwnica-Worms D: Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant {beta}-catenin activation in colon cancer. Clin Cancer Res. 15:7529–7537. 2009. View Article : Google Scholar : PubMed/NCBI
23	Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC and Druker BJ: RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA. 106:8695–8700. 2009. View Article : Google Scholar : PubMed/NCBI
24	Giamas G, Filipović A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, et al: Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 17:715–719. 2011. View Article : Google Scholar : PubMed/NCBI
25	Nikiforov YE: Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 135:569–577. 2011.PubMed/NCBI
26	Shi H, Li Q, Ji M, Wu J, Li Z, Zheng X, Xu B, Chen L, Li X, Lu C, et al: Lemur tyrosine kinase-3 is a significant prognostic marker for patients with colorectal cancer. Int J Clin Exp Pathol. 7:1101–1107. 2014.PubMed/NCBI
27	Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, Lenz HJ, Coombes RC, Wang T, Lee SC and Giamas G: LMTK3 expression in breast cancer: Association with tumor phenotype and clinical outcome. Breast Cancer Res Treat. 132:537–544. 2012. View Article : Google Scholar : PubMed/NCBI
28	Li Z, Wu J, Ji M, Shi L, Xu B, Jiang J and Wu C: Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer. Mol Clin Oncol. 2:756–760. 2014.PubMed/NCBI
29	Fan Y, Chen M, Meng J, Yu L, Tu Y, Wan L, Fang K and Zhu W: Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity. PLoS One. 9:e1058902014. View Article : Google Scholar : PubMed/NCBI
30	Shi H, Wu J, Ji M, Zhou Q, Li Z, Zheng X, Xu B, Deng H, Zhao W, Wu C and Jiang J: Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis. Med Oncol. 30:7542013. View Article : Google Scholar : PubMed/NCBI
31	Xu Z, Qi X, Zhang X and Yu L: Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer. Tumour Biol. 35:5007–5011. 2014. View Article : Google Scholar : PubMed/NCBI
32	Zhao G, Guo J, Li D, Jia C, Yin W, Sun R, Lv Z and Cong X: MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. DNA Cell Biol. 32:699–707. 2013. View Article : Google Scholar : PubMed/NCBI